Pyochelin potentiates the inhibitory activity of gallium on Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5572-5575

  Frangipani, Emanuela ^a   Bonchi, Carlo ^a   Minandri, Fabrizia ^a   Imperi, Francesco ^b   Visca, Paolo ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; GALLIUM; PYOCHELIN; SIDEROPHORE; TRANSLOCON; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CITRATE SODIUM; CITRIC ACID; DEFEROXAMINE; DRUG COMBINATION; FERRICHROME; OLIGOPEPTIDE; PHENOL DERIVATIVE; PYOVERDINE; THIAZOLE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; COMPLEX FORMATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; TRANSPORT AT THE CELLULAR LEVEL;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CITRATES; DEFEROXAMINE; DRUG COMBINATIONS; DRUG SYNERGISM; FERRICHROME; GALLIUM; OLIGOPEPTIDES; PHENOLS; PSEUDOMONAS AERUGINOSA; SIDEROPHORES; THIAZOLES;

EID: 84906074895     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03154-14     Document Type: Article

References (21)

1. Andrews SC, Robinson AK, Rodríguez-Quiñones F. 2003. Bacterial iron homeostasis. FEMS Microbiol. Rev. 27:215-237. http://dx.doi.org/10.1016/S0168-6445(03)00055-X. (Pubitemid 36694657)
2. Weinberg ED. 2009. Iron availability and infection. Biochim. Biophys. Acta 1790:600-605. http://dx.doi.org/10.1016/j.bbagen.2008.07.002.
3. Krewulak KD, Vogel HJ. 2008. Structural biology of bacterial iron uptake. Biochim. Biophys. Acta 1778:1781-1804. http://dx.doi.org/10.1016/j.bbamem.2007. 07.026.
4. Ballouche M, Cornelis P, Baysse C. 2009. Iron metabolism: a promising target for antibacterial strategies. Recent Pat. Antiinfect. Drug Discov. 4:190-205. http://dx.doi.org/10.2174/157489109789318514.
5. Möllmann U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D. 2009. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 22:615-624. http://dx.doi.org/10.1007/s10534- 009-9219-2.
6. Foley TL, Simeonov A. 2012. Targeting iron assimilation to develop new antibacterials. Expert Opin. Drug Discov. 7:831-847. http://dx.doi.org/10.1517/ 17460441.2012.708335.
7. Imperi F, Massai F, Facchini M, Frangipani E, Visaggio D, Leoni L, Bragonzi A, Visca P. 2013. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc. Natl. Acad. Sci. U. S. A. 110:7458-7463. http://dx.doi.org/10.1073/pnas.1222706110.
8. Bernstein LR. 1998. Mechanisms of therapeutic activity for gallium. Pharmacol. Rev. 50:665-682. (Pubitemid 29028814)
9. Bernstein LR. 2013. Gallium, therapeutic effects, p 823- 835. In Kretsinger RH, Uversky VN, Permyakov EA (ed), Encyclopedia of metalloproteins. Springer, New York, NY.
10. Kelson AB, Carnevali M, Truong-Le V. 2013. Gallium-based antiinfectives: targeting microbial iron-uptake mechanisms. Curr. Opin. Pharmacol. 13:707-771. http://dx.doi.org/10.1016/j.coph.2013.07.001.
11. Bonchi C, Imperi F, Minandri F, Visca P, Frangipani E. 2014. Repurposing of gallium-based drugs for antibacterial therapy. Biofactors 40:303-312. http://dx.doi.org/10.1002/biof.1159.
12. Minandri F, Bonchi C, Frangipani E, Imperi F, Visca P. 2014. Promises and failures of gallium as an antibacterial agent. Future Microbiol. 9:379-397. http://dx.doi.org/10.2217/fmb.14.3.
13. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK. 2007. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 117:877-888. http://dx.doi.org/10.1172/JCI30783. (Pubitemid 46556744)
14. Banin E, Lozinski A, Brady KM, Berenshtein E, Butterfield PW, Moshe M, Chevion M, Greenberg EP, Banin E. 2008. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc. Natl. Acad. Sci. U. S. A. 105:16761-16766. http://dx.doi.org/10.1073/pnas.0808608105.
15. Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Döring G, Tümmler B. 2009. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am. J. Respir. Crit. Care Med. 180:138-145. http://dx.doi.org/10.1164/rccm. 200812-1943OC.
16. Imperi F, Putignani L, Tiburzi F, Ambrosi C, Cipollone R, Ascenzi P, Visca P. 2008. Membrane-association determinants of the omega-amino acid monooxygenase PvdA, a pyoverdine biosynthetic enzyme from Pseudomonas aeruginosa. Microbiology 154:2804-2813. http://dx.doi.org/10.1099/mic.0.2008/ 018804-0.
17. Cox CD, Graham R. 1979. Isolation of an iron-binding compound from Pseudomonas aeruginosa. J. Bacteriol. 137:357-364. (Pubitemid 9097580)
18. Visca P, Ciervo A, Sanfilippo V, Orsi N. 1993. Iron-regulated salicylate synthesis by Pseudomonas spp. J. Gen. Microbiol. 139:1995-2001. http://dx.doi.org/10.1099/00221287-139-9-1995. (Pubitemid 23284966)
19. Meyer JM, Stintzi A, De Vos D, Cornelis P, Tappe R, Taraz K, Budzikiewicz H. 1997. Use of siderophores to type pseudomonads: the three Pseudomonas aeruginosa pyoverdine systems. Microbiology 143:35-43. http://dx.doi.org/10. 1099/00221287-143-1-35. (Pubitemid 27072957)
20. Reimmann C. 2012. Inner-membrane transporters for the siderophores pyochelin in Pseudomonas aeruginosa and enantio-pyochelin in Pseudomonas fluorescens display different enantioselectivities. Microbiology 158:1317-1324. http://dx.doi.org/10.1099/mic.0.057430-0.
21. García-Contreras R, Lira-Silva E, Jasso-Chávez R, Hernández-González IL, Maeda T, Hashimoto T, Boogerd FC, Sheng L, Wood TK, Moreno-Sánchez R. 2013. Isolation and characterization of gallium resistant Pseudomonas aeruginosa mutants. Int. J. Med. Microbiol. 303:574-582. http://dx.doi.org/10.1016/j.ijmm.2013.07.009.